We can learn a considerable amount about transapical approach from the vast experience gained from treating patients with aortic stenosis. Transapical access was highly utilized in the first decade of transcatheter aortic valve replacement but its use has since decreased dramatically (6) . This decline is directly related to a reduction in the required sheath size, enabling safe transfemoral artery delivery and a paradigm shift aiming to treat high-risk patients using a less-invasive minimalist approach. In addition substantial clinical data suggest that transapical approach is associated with worse clinical outcomes that cannot be explained solely by dissimilar patient characteristics (7) (8) (9) (10) . Transapical approach can occasionally lead to the impairment of left ventricular apical function (11, 12) . This deterioration in ventric- Currently available retrievable devices ‡ ‡ ‡ Using a longer transcatheter heart valve § § § Using a smaller and better trackable delivery system § § § *These considerations are based mainly on personal clinical experience and only little on scientific data. †Left atrial approach, which includes several of the advantages and limitations of the transapical approach, was not included in this table because of relatively limited worldwide transcatheter clinical practice. ‡Intended for either transfemoral or transjugular venous access. The vast majority of transseptal cases that were performed worldwide were via the femoral vein. §Cases at need for more atrial position: high risk for left ventricular outflow tract obstruction; cases at need for more ventricular position: small surgical valve label size #25 mm, considering no long-term anticoagulation. kSuch as in cases with very small mitral valve orifice area. In general, crossing a stenotic valve retrogradely (transapical) is more challenging then crossing a valve antegradely (transseptal), however, not being able to cross with a transcatheter valve located in the left atrium may cause serious implications. ¶Such as in patients with chronic lung disease. #Including left atrial appendage closure, electrophysiological procedure. **Transesophageal echocardiogram could be performed during transseptal puncture only or puncture be guided by intracardiac echocardiography. † †Diminutive peripheral veins, active deep vein thrombosis, inferior vena cava filter, and numerous pacemaker cables in left atrium. ‡ ‡Including previous atrial septal defect closure. kkThrombus in the left atrial cavity or appendage could be considered a contraindication for transapical implantation as well but is more of a concern when manipulation in the left atrium is required. ¶ ¶Data from aortic stenosis therapy suggests that transapical is independently more associated with acute kidney injury than transfemoral access. ##Such as Epic valve (St. Jude Medical, Minneapolis, Minnesota). ***All those with label size 25 mm and those with true internal diameter #22 mm. In these cases highly accurate and more ventricular implantation could be hemodynamically advantageous. † † †Paravalvular leakage of mild or uncertain significance can increase after valve in valve. Performing the procedure through the heart apex may improve the capability to deploy a closure device successfully. ‡ ‡ ‡Retrievable devices such as DirectFlow 
